Such protective effects have been observed with PPARγ agonist use in models of ischemic and hemorrhagic stroke [153–158], and in models of CNS disease including Alzheimer's disease, multiple sclerosis (MS), amyotrophic lateral sclerosis, and Parkinson's disease [152]. The gene discussed is PPARG; the disease is amyotrophic lateral sclerosis.